utilizing state-of-the-art instruments like GEPIA [30], UALCAN [31], and STRING [32], we aim to elucidate the molecular mechanisms underlying p53 dysregulation in cancer and identify novel therapeutic opportunities for personalized cancer management. This evidence concerns the gene TP53 and cancer.